[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+82-32-850-6594

Email address

BoYoung.Choi@Celltrion.com

Condition

Rheumatoid Arthritis

Treatment type

Observational [Patient Registry]

Phase

N/A

Sponsor

Celltrion

ClinicalTrials.gov identifier

NCT02557295

Study number

CT-P13 4.2

Date first posted

March 18, 2015

Date last update

June 12, 2017

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Rheumatoid Arthritis.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. applicable) who are willing to give informed consent for long term follow-up including access to all medical records
Exclusion criteria

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site